Skip to content
Screener

Tandem Diabetes Care TNDM Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Beta Bionics logo
Beta BionicsBBNX
-$23.7M-39.7%
InfuSystem Holdings logo
InfuSystem HoldingsINFU
$1.03M+299%
Senseonics Holdings, Inc. logo
Senseonics Holdings, Inc.SENS
-$36.77M-154%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$234.79M+67.5%
Tempus AI, Inc. logo
Tempus AI, Inc.TEM
$4.61M+112%
Medtronic logo
MedtronicMDT

Other financials

Income statement

See full
Revenue$254.6M+5.8%
Gross profit$144.8M+15.0%
Operating income-$13.8M+73.4%
Net income-$21.2M+59.6%
EPS (diluted)-$0.31+60.3%

Balance sheet

See full
Cash & equivalents$62.8M-2.0%
Total debt$739.3M+64.6%
Total equity$130.4M-2.2%
Total assets$1.2B+31.8%

Cash flow

See full
Operating cash flow-$34.6M-265%
CapEx$4.1M-34.7%
Free cash flow-$38.7M-146%

Valuation

See full
Market cap$1.56B+128%
Enterprise value$2.23B+109%
P/S1.5×+0.8×

Profitability

See full
Gross margin56%+3.5pp
Operating margin-4.4%-1.9pp
Net margin-6.1%-2.5pp
FCF margin-0.8%-0.4pp

Returns & leverage

See full
Return on equity-48%-17.5pp
Debt / equity5.7×+2.3×
Current ratio3.2×+0.7×

Where this comes from

Reported directly by Tandem Diabetes Care in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:11 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001438133-26-000125
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Net loss$(21,168)$(52,400)$(41,561)$(182,956)
Other comprehensive income (loss):
Unrealized gain (loss) on short-term investments$(692)$(98)$(1,719)$325
Unrealized gain (loss) on cash flow hedges716(612)2,418(612)
Foreign currency translation gains1,3354,3801115,979
Comprehensive loss$(19,809)$(48,730)$(40,751)$(177,264)
Net loss per share - basic and diluted$(0.31)$(0.78)$(0.60)$(2.74)
Weighted average shares used to compute basic and diluted net loss per share69,01167,05068,70666,729

Item 1. Financial Statements.

FAQ

What is Tandem Diabetes Care's comprehensive income (loss), net of tax, attributable to parent?
Tandem Diabetes Care (TNDM) reported comprehensive income (loss), net of tax, attributable to parent of -$19.81M in Q2 2026.
How has Tandem Diabetes Care's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Tandem Diabetes Care's comprehensive income (loss), net of tax, attributable to parent increased by 59.3% year-over-year, from -$48.73M to -$19.81M.
What is the long-term trend for Tandem Diabetes Care's comprehensive income (loss), net of tax, attributable to parent?
Over 4 years (2021 to 2025), Tandem Diabetes Care's comprehensive income (loss), net of tax, attributable to parent has grown at a 91.3% compound annual growth rate (CAGR), from $14.73M to -$197.17M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This is a comprehensive measure of the company's financial performance that includes net income plus other gains and losses that are excluded from the traditional income statement. It provides a broader view of the company's total change in equity resulting from non-owner sources. Investors use this to evaluate the total economic impact of all financial activities, including market-driven fluctuations and hedging outcomes.

Ask your AI about Tandem Diabetes Care's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude